title: Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia.
abstract: BACKGROUND
  Hodgkin lymphoma (HL) exhibits considerable clinicopathological variations in different parts of the world. This study was prompted by the limited availability of HL data in developing countries (particularly long-term outcomes).
  
  
  METHODS
  We performed a retrospective review of eligible adult HL patients treated at 3 tertiary centers in Saudi Arabia between January 1997 and December 2012.
  
  
  RESULTS
  The review included 340 patients with a median age of 26 years (range 15-82 years); 53% were male, 74% had an advanced stage, 22% had bulky disease, and 70% had low-to-intermediate risk according to the International Prognostic Score. Nodular sclerosis was the most common histological subtype (59%). Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) was offered to 92% and radiotherapy to 43%. Initial therapy outcomes were complete response, partial response, and progressive disease in 91%, 5%, and 2% of patients, respectively. At a median follow-up of 39 months, the actuarial freedom from treatment failure at 5 years was 74%, with a 5-year overall survival of 91%. Multivariate analysis showed that advanced disease stage and high-risk international prognostic index independently predicted an adverse outcome.
  
  
  CONCLUSIONS
  Our Saudi patient population exhibited outcomes that were comparable to those reported in developed countries.
authors.forename: Ruaa G
authors.initials: RG
authors.lastname: Shafi
authors.forename: Mubarak M
authors.initials: MM
authors.lastname: Al-Mansour
authors.forename: Solaf S
authors.initials: SS
authors.lastname: Kanfar
authors.forename: Hani
authors.initials: H
authors.lastname: Al Hashmi
authors.forename: Ahmed
authors.initials: A
authors.lastname: Alsaeed
authors.forename: Meteb
authors.initials: M
authors.lastname: Al-Foheidi
authors.forename: Ezzeldin M
authors.initials: EM
authors.lastname: Ibrahim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D059248:Chemoradiotherapy / Q000401:mortality* / Q000706:statistics & numerical data*; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D012529:Saudi Arabia / Q000453:epidemiology; D015996:Survival Rate; D055815:Young Adult
keywords: Hodgkin lymphoma; Outcome assessment; Prognosis